黑色素瘤的新疗法

S. Legha
{"title":"黑色素瘤的新疗法","authors":"S. Legha","doi":"10.12788/j.cmonc.0081","DOIUrl":null,"url":null,"abstract":"Metastatic melanoma is a highly challenging cancer to treat. Like other solid tumors, it is a very heterogeneous disease both clinically and biologically. Consequently, the first decision point in its management is to assess the severity of an individual patient’s disease. This can be done based on the patient’s symptoms and how they have evolved over the preceding 1-2 months, performance status, the extent of disease as determined by physical examination, and staging workup, which should include either computed tomography scans of the body or a positron emission tomography/CT study as well as a brain magnetic resonance imaging scan. Patients with brain metastases as a subset (which is sizable – 20%-25% have brain metastases) require special attention because they may not respond to systemic therapies and will thus have to be managed with brain-targeted treatment options. Tumor testing for BRAF mutations is necessary in all patients with metastatic melanoma because the BRAF inhibitors (vemurafenib or dabrafenib) are a preferred choice of targeted therapy for this subset of patients, which constitutes about 50% of all melanoma patients. Immunotherapy plays an important role in nearly all patients with metastatic melanoma including those who have progressed after anti-BRAF therapy. Chemotherapy still has a significant (yet diminishing) role for patients who are no longer suitable for immunotherapy. Targeted therapy is the preferred choice of therapy provided the tumor has presence of BRAF mutations. The first targeted therapy agent shown to have a high level of activity was the BRAF inhibitor vemurafenib, which was approved by the Food and Drug Administration in 2011. This drug has produced objective responses in more than 50% of BRAF-mutated melanoma cases and the onset of response is rapid, especially in patients who have large loads of metastatic tumor. However, the responses are not durable and typically last about 6 months before the tumor begins to progress again. The second BRAF inhibitor, dabrafenib, was approved by the FDA in May 2013 on the basis of its single-agent activity, which was similar to that of vemurafenib. MEK inhibitors are also active in advanced melanoma although the response rates are lower (22%). One such drug, trametinib, also received FDA approval in May 2013 for single-agent use in BRAF-positive melanomas. Because of their short duration of response, targeted agents are now being tested in combination with other agents. The first such attempt used a combination of dabrafenib and trametinib and the results of the phase 1-2 study showed response rates of nearly 70% and a response duration that was more than 9 months longer compared with the individual single agents (5.8 months). Immune stimulation as a form of anticancer therapy has played a more important role in managing melanoma than in any other cancer. Responses were observed in a minority of patients yet the responses were frequently quite durable and the responders often achieved longterm control (cure) of their advanced cancer. The first bona fide immunotherapy to be approved by the Food and Drug Administration for treatment of melanoma was high-dose interleukin-2, which actually did not prolong the overall survival but produced long-term remissions in 10% of the patients who were ultimately cured of their disease. Ipilimumab was the next active immunotherapy and for the first time resulted in a significant increase in the survival of patients with metastatic melanoma, although it benefited only 10%-15% of patients who were treated with it. However, the responses were durable, often lasting longer than 5-10 years. It received FDA approval in 2011 and is now used for a majority of patients with metastatic melanoma. More recently, a better understanding of the workings of the human immune system has lead to the discovery of the programmed cell death 1 (PD-1) and programmed cell death 1 ligand (PD-L1) immune checkpoint pathways, which are responsible for the often observed paralysis of the immune system in patients with metastatic cancer. Consequently several antibodies toward these immune checkpoint markers have entered into clinical trials and have shown remarkable anticancer activity in melanoma as well as in some other solid tumors. Three drugs, nivolumab, lambrolizumab, and MPDL3280A, have now","PeriodicalId":72649,"journal":{"name":"Community oncology","volume":"10 1","pages":"340-341"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging therapies for melanoma\",\"authors\":\"S. Legha\",\"doi\":\"10.12788/j.cmonc.0081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metastatic melanoma is a highly challenging cancer to treat. Like other solid tumors, it is a very heterogeneous disease both clinically and biologically. Consequently, the first decision point in its management is to assess the severity of an individual patient’s disease. This can be done based on the patient’s symptoms and how they have evolved over the preceding 1-2 months, performance status, the extent of disease as determined by physical examination, and staging workup, which should include either computed tomography scans of the body or a positron emission tomography/CT study as well as a brain magnetic resonance imaging scan. Patients with brain metastases as a subset (which is sizable – 20%-25% have brain metastases) require special attention because they may not respond to systemic therapies and will thus have to be managed with brain-targeted treatment options. Tumor testing for BRAF mutations is necessary in all patients with metastatic melanoma because the BRAF inhibitors (vemurafenib or dabrafenib) are a preferred choice of targeted therapy for this subset of patients, which constitutes about 50% of all melanoma patients. Immunotherapy plays an important role in nearly all patients with metastatic melanoma including those who have progressed after anti-BRAF therapy. Chemotherapy still has a significant (yet diminishing) role for patients who are no longer suitable for immunotherapy. Targeted therapy is the preferred choice of therapy provided the tumor has presence of BRAF mutations. The first targeted therapy agent shown to have a high level of activity was the BRAF inhibitor vemurafenib, which was approved by the Food and Drug Administration in 2011. This drug has produced objective responses in more than 50% of BRAF-mutated melanoma cases and the onset of response is rapid, especially in patients who have large loads of metastatic tumor. However, the responses are not durable and typically last about 6 months before the tumor begins to progress again. The second BRAF inhibitor, dabrafenib, was approved by the FDA in May 2013 on the basis of its single-agent activity, which was similar to that of vemurafenib. MEK inhibitors are also active in advanced melanoma although the response rates are lower (22%). One such drug, trametinib, also received FDA approval in May 2013 for single-agent use in BRAF-positive melanomas. Because of their short duration of response, targeted agents are now being tested in combination with other agents. The first such attempt used a combination of dabrafenib and trametinib and the results of the phase 1-2 study showed response rates of nearly 70% and a response duration that was more than 9 months longer compared with the individual single agents (5.8 months). Immune stimulation as a form of anticancer therapy has played a more important role in managing melanoma than in any other cancer. Responses were observed in a minority of patients yet the responses were frequently quite durable and the responders often achieved longterm control (cure) of their advanced cancer. The first bona fide immunotherapy to be approved by the Food and Drug Administration for treatment of melanoma was high-dose interleukin-2, which actually did not prolong the overall survival but produced long-term remissions in 10% of the patients who were ultimately cured of their disease. Ipilimumab was the next active immunotherapy and for the first time resulted in a significant increase in the survival of patients with metastatic melanoma, although it benefited only 10%-15% of patients who were treated with it. However, the responses were durable, often lasting longer than 5-10 years. It received FDA approval in 2011 and is now used for a majority of patients with metastatic melanoma. More recently, a better understanding of the workings of the human immune system has lead to the discovery of the programmed cell death 1 (PD-1) and programmed cell death 1 ligand (PD-L1) immune checkpoint pathways, which are responsible for the often observed paralysis of the immune system in patients with metastatic cancer. Consequently several antibodies toward these immune checkpoint markers have entered into clinical trials and have shown remarkable anticancer activity in melanoma as well as in some other solid tumors. Three drugs, nivolumab, lambrolizumab, and MPDL3280A, have now\",\"PeriodicalId\":72649,\"journal\":{\"name\":\"Community oncology\",\"volume\":\"10 1\",\"pages\":\"340-341\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Community oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/j.cmonc.0081\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Community oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.cmonc.0081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

转移性黑色素瘤是一种极具挑战性的癌症。像其他实体瘤一样,它在临床和生物学上都是一种异质性很强的疾病。因此,其管理的第一个决策点是评估个体患者疾病的严重程度。这可以根据患者的症状及其在过去1-2个月的演变情况、表现状况、体检确定的疾病程度以及分期检查来完成,分期检查应包括身体计算机断层扫描或正电子发射断层扫描/CT研究以及脑磁共振成像扫描。脑转移患者作为一个子集(占相当大的比例,20%-25%有脑转移)需要特别注意,因为他们可能对全身治疗没有反应,因此必须采用脑靶向治疗方案进行管理。BRAF突变的肿瘤检测对于所有转移性黑色素瘤患者都是必要的,因为BRAF抑制剂(vemurafenib或dabrafenib)是这部分患者的首选靶向治疗,这部分患者约占所有黑色素瘤患者的50%。免疫治疗在几乎所有的转移性黑色素瘤患者中起着重要的作用,包括那些在抗braf治疗后进展的患者。对于不再适合免疫治疗的患者,化疗仍然具有重要(但正在减弱)的作用。如果肿瘤存在BRAF突变,靶向治疗是首选的治疗方法。第一个被证明具有高水平活性的靶向治疗药物是BRAF抑制剂vemurafenib,该药物于2011年获得美国食品和药物管理局(fda)的批准。该药物在超过50%的braf突变黑色素瘤病例中产生了客观反应,并且反应的发生迅速,特别是在转移性肿瘤负荷较大的患者中。然而,这种反应并不持久,通常在肿瘤再次开始进展之前持续约6个月。第二种BRAF抑制剂dabrafenib于2013年5月获得FDA批准,基于其单药活性,与vemurafenib相似。MEK抑制剂在晚期黑色素瘤中也有活性,尽管反应率较低(22%)。其中一种此类药物曲美替尼(trametinib)也于2013年5月获得FDA批准,可用于braf阳性黑色素瘤的单药治疗。由于靶向药物的反应时间短,目前正在与其他药物联合试验。第一次这样的尝试使用了dabrafenib和trametinib的联合治疗,1-2期研究的结果显示,与单个药物(5.8个月)相比,反应率接近70%,反应持续时间超过9个月。免疫刺激作为抗癌治疗的一种形式,在治疗黑色素瘤方面发挥了比其他任何癌症更重要的作用。在少数患者中观察到反应,但反应通常相当持久,反应者通常达到晚期癌症的长期控制(治愈)。美国食品和药物管理局批准的第一个治疗黑色素瘤的真正意义上的免疫疗法是高剂量的白介素-2,它实际上并没有延长总体生存期,但在10%的患者中产生了长期缓解,最终治愈了他们的疾病。Ipilimumab是下一个主动免疫疗法,它首次显著提高了转移性黑色素瘤患者的生存率,尽管只有10%-15%的患者受益。然而,这些反应是持久的,通常持续时间超过5-10年。它在2011年获得了FDA的批准,现在被用于大多数转移性黑色素瘤患者。最近,对人类免疫系统工作的更好理解导致了程序性细胞死亡1 (PD-1)和程序性细胞死亡1配体(PD-L1)免疫检查点途径的发现,这是导致转移性癌症患者经常观察到的免疫系统瘫痪的原因。因此,针对这些免疫检查点标记的几种抗体已进入临床试验,并在黑色素瘤和其他一些实体瘤中显示出显著的抗癌活性。目前,nivolumab、lambrolizumab和MPDL3280A这三种药物已经上市
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Emerging therapies for melanoma
Metastatic melanoma is a highly challenging cancer to treat. Like other solid tumors, it is a very heterogeneous disease both clinically and biologically. Consequently, the first decision point in its management is to assess the severity of an individual patient’s disease. This can be done based on the patient’s symptoms and how they have evolved over the preceding 1-2 months, performance status, the extent of disease as determined by physical examination, and staging workup, which should include either computed tomography scans of the body or a positron emission tomography/CT study as well as a brain magnetic resonance imaging scan. Patients with brain metastases as a subset (which is sizable – 20%-25% have brain metastases) require special attention because they may not respond to systemic therapies and will thus have to be managed with brain-targeted treatment options. Tumor testing for BRAF mutations is necessary in all patients with metastatic melanoma because the BRAF inhibitors (vemurafenib or dabrafenib) are a preferred choice of targeted therapy for this subset of patients, which constitutes about 50% of all melanoma patients. Immunotherapy plays an important role in nearly all patients with metastatic melanoma including those who have progressed after anti-BRAF therapy. Chemotherapy still has a significant (yet diminishing) role for patients who are no longer suitable for immunotherapy. Targeted therapy is the preferred choice of therapy provided the tumor has presence of BRAF mutations. The first targeted therapy agent shown to have a high level of activity was the BRAF inhibitor vemurafenib, which was approved by the Food and Drug Administration in 2011. This drug has produced objective responses in more than 50% of BRAF-mutated melanoma cases and the onset of response is rapid, especially in patients who have large loads of metastatic tumor. However, the responses are not durable and typically last about 6 months before the tumor begins to progress again. The second BRAF inhibitor, dabrafenib, was approved by the FDA in May 2013 on the basis of its single-agent activity, which was similar to that of vemurafenib. MEK inhibitors are also active in advanced melanoma although the response rates are lower (22%). One such drug, trametinib, also received FDA approval in May 2013 for single-agent use in BRAF-positive melanomas. Because of their short duration of response, targeted agents are now being tested in combination with other agents. The first such attempt used a combination of dabrafenib and trametinib and the results of the phase 1-2 study showed response rates of nearly 70% and a response duration that was more than 9 months longer compared with the individual single agents (5.8 months). Immune stimulation as a form of anticancer therapy has played a more important role in managing melanoma than in any other cancer. Responses were observed in a minority of patients yet the responses were frequently quite durable and the responders often achieved longterm control (cure) of their advanced cancer. The first bona fide immunotherapy to be approved by the Food and Drug Administration for treatment of melanoma was high-dose interleukin-2, which actually did not prolong the overall survival but produced long-term remissions in 10% of the patients who were ultimately cured of their disease. Ipilimumab was the next active immunotherapy and for the first time resulted in a significant increase in the survival of patients with metastatic melanoma, although it benefited only 10%-15% of patients who were treated with it. However, the responses were durable, often lasting longer than 5-10 years. It received FDA approval in 2011 and is now used for a majority of patients with metastatic melanoma. More recently, a better understanding of the workings of the human immune system has lead to the discovery of the programmed cell death 1 (PD-1) and programmed cell death 1 ligand (PD-L1) immune checkpoint pathways, which are responsible for the often observed paralysis of the immune system in patients with metastatic cancer. Consequently several antibodies toward these immune checkpoint markers have entered into clinical trials and have shown remarkable anticancer activity in melanoma as well as in some other solid tumors. Three drugs, nivolumab, lambrolizumab, and MPDL3280A, have now
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Conceptual changes needed to improve outcomes in rehabilitation medicine: A clinical commentary. Riding the wave Renal failure in multiple myeloma Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration Cost and response criteria are the new challenges
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1